RCMI Coordinating Center (RCMI CC) Header Logo

Cornelis Vlaar

TitlePhD
Faculty RankProfessor
InstitutionUniversity of Puerto Rico
DepartmentSchool of Pharmacy
AddressUPR- Medical Sciences Campus, School of Pharmacy
San Juan PR 936
Phone7877582525 exts.: 5412, 5432
ORCID ORCID Icon0000-0001-5145-8300 Additional info
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    Academic Position
    Dr. Cornelis Vlaar is Professor at the School of Pharmacy, University of Puerto Rico Medical Sciences Campus, where since 2012 he also serves as Chair of the Department of Pharmaceutical Sciences.

    Education
    Dr. Vlaar received his doctoral degree in Organic Chemistry from the Vrije Universiteit in Amsterdam, The Netherlands. He conducted post doctoral studies in Louisiana State University and The Scripss Research Institute.

    Research Area
    Biologically active molecules.

    Description of research interests
    Dr. Vlaar research targets organic molecules with biological activity which can be used as enzyme inhibitors as well as therapeutic agents.

    Research Funding
    Research activities are currently supported by the NIGMS MBRS-SCORE program; Previously, research was supported via INDUNIV, a local research consortium, and institutional funds from the NCRR-RCMI program at the University of Puerto Rico Medical Sciences Campus.

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Vel?zquez-Vega LE, Rivera-Robles M, S?nchez-?lvarez AO, Vivas-Mej?a PE, Aponte-Reyes M, Cruz-Collazo AM, Grafals-Ruiz N, Dorta-Estremera S, Hern?ndez-O'Farrill E, Vlaar CP, Dharmawardhane S. Efficacy and delivery strategies of the dual Rac/Cdc42 inhibitor MBQ-167 in HER2 overexpressing breast cancer. Transl Oncol. 2024 Jun; 44:101928. PMID: 38489873.
      Citations:    
    2. Rodr?guez-Fern?ndez K, Reynaldo-Fern?ndez G, Reyes-Gonz?lez S, de Las Barreras C, Rodr?guez-Vera L, Vlaar C, Monbaliu JM, Stelzer T, Duconge J, Mangas-Sanjuan V. New insights into the role of VKORC1 polymorphisms for optimal warfarin dose selection in Caribbean Hispanic patients through an external validation of a population PK/PD model. Biomed Pharmacother. 2024 Jan; 170:115977. PMID: 38056237.
      Citations:    Fields:    Translation:Humans
    3. Crespo GV, Ortiz J, O'Farrill EH, Vlaar CP, Inyushin M, Kucheryavykh Y, Kucheryavykh L. The Rac inhibitor HV-107 as a potential therapeutic for metastatic breast cancer. Mol Med. 2023 06 14; 29(1):75. PMID: 37316799.
      Citations:    Fields:    Translation:HumansAnimals
    4. Medina JI, Cruz-Collazo A, Del Mar Maldonado M, Gascot TM, Borrero-Garcia LD, Cooke M, Kazanietz MG, O'Farril EH, Vlaar CP, Dharmawardhane S. Characterization of Novel Derivatives of MBQ-167, an inhibitor of the GTP-binding proteins Rac/Cdc42. Cancer Res Commun. 2022 12; 2(12):1711-1726. PMID: 36861094.
      Citations: 3     Fields:    Translation:Animals
    5. Cruz-Collazo A, Ruiz-Calderon JF, Picon H, Borrero-Garcia LD, Lopez I, Castillo-Pichardo L, Del Mar Maldonado M, Duconge J, Medina JI, Bayro MJ, Hern?ndez-O'Farrill E, Vlaar CP, Dharmawardhane S. Efficacy of Rac and Cdc42 Inhibitor MBQ-167 in Triple-negative Breast Cancer. Mol Cancer Ther. 2021 12; 20(12):2420-2432. PMID: 34607932.
      Citations: 7     Fields:    Translation:HumansAnimalsCells
    6. Jim?nez Cruz JM, Vlaar CP, Stelzer T, L?pez-Mej?as V. Polymorphism in early development: The account of MBQ-167. Int J Pharm. 2021 Oct 25; 608:121064. PMID: 34481010.
      Citations:    Fields:    Translation:Cells
    7. Jim?nez Cruz JM, Vlaar CP, L?pez-Mej?as V, Stelzer T. Solubility Measurements and Correlation of MBQ-167 in Neat and Binary Solvent Mixtures. J Chem Eng Data. 2021 Jan 14; 66(1):832-839. PMID: 36262318.
      Citations:    
    8. Reyes-Gonz?lez S, de Las Barreras C, Reynaldo G, Rodr?guez-Vera L, Vlaar C, Mejias VL, Monbaliu JM, Stelzer T, Mangas V, Duconge J. Genotype-driven pharmacokinetic simulations of warfarin levels in Puerto Ricans. Drug Metab Pers Ther. 2020 Aug 19. PMID: 32809952.
      Citations: 1     Fields:    
    9. Reyes-Gonz?lez S, de Las Barreras C, Reynaldo G, Rodr?guez-Vera L, Vlaar C, Mejias VL, Monbaliu JM, Stelzer T, Mangas V, Duconge J. Genotype-driven pharmacokinetic simulations of warfarin levels in Puerto Ricans. Drug Metab Pers Ther. 2020 08 18; 35(4). PMID: 34704696.
      Citations:    Fields:    Translation:Humans
    10. Maldonado MDM, Rosado-Gonz?lez G, Bloom J, Duconge J, Ruiz-Calder?n JF, Hern?ndez-O'Farrill E, Vlaar C, Rodr?guez-Orengo JF, Dharmawardhane S. Pharmacokinetics of the Rac/Cdc42 Inhibitor MBQ-167 in Mice by Supercritical Fluid Chromatography-Tandem Mass Spectrometry. ACS Omega. 2019 Nov 05; 4(19):17981-17989. PMID: 31720502.
      Citations:    
    11. Vlaar CP, Castillo-Pichardo L, Medina JI, Marrero-Serra CM, V?lez E, Ramos Z, Hern?ndez E. Design, synthesis and biological evaluation of new carbazole derivatives as anti-cancer and anti-migratory agents. Bioorg Med Chem. 2018 02 15; 26(4):884-890. PMID: 29358027.
      Citations: 7     Fields:    Translation:HumansCells
    12. Humphries-Bickley T, Castillo-Pichardo L, Hernandez-O'Farrill E, Borrero-Garcia LD, Forestier-Roman I, Gerena Y, Blanco M, Rivera-Robles MJ, Rodriguez-Medina JR, Cubano LA, Vlaar CP, Dharmawardhane S. Characterization of a Dual Rac/Cdc42 Inhibitor MBQ-167 in Metastatic Cancer. Mol Cancer Ther. 2017 05; 16(5):805-818. PMID: 28450422.
      Citations: 45     Fields:    Translation:HumansAnimalsCells
    13. Veluthakal R, Tunduguru R, Arora DK, Sidarala V, Syeda K, Vlaar CP, Thurmond DC, Kowluru A. VAV2, a guanine nucleotide exchange factor for Rac1, regulates glucose-stimulated insulin secretion in pancreatic beta cells. Diabetologia. 2015 Nov; 58(11):2573-81. PMID: 26224100.
      Citations: 27     Fields:    Translation:HumansAnimalsCells
    14. Sidarala V, Veluthakal R, Syeda K, Vlaar C, Newsholme P, Kowluru A. Phagocyte-like NADPH oxidase (Nox2) promotes activation of p38MAPK in pancreatic ?-cells under glucotoxic conditions: Evidence for a requisite role of Ras-related C3 botulinum toxin substrate 1 (Rac1). Biochem Pharmacol. 2015 Jun 15; 95(4):301-10. PMID: 25881746.
      Citations: 26     Fields:    Translation:AnimalsCells
    15. Humphries-Bickley T, Castillo-Pichardo L, Corujo-Carro F, Duconge J, Hernandez-O'Farrill E, Vlaar C, Rodriguez-Orengo JF, Cubano L, Dharmawardhane S. Pharmacokinetics of Rac inhibitor EHop-016 in mice by ultra-performance liquid chromatography tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2015 Feb 15; 981-982:19-26. PMID: 25594952.
      Citations: 18     Fields:    Translation:Animals
    16. Castillo-Pichardo L, Humphries-Bickley T, De La Parra C, Forestier-Roman I, Martinez-Ferrer M, Hernandez E, Vlaar C, Ferrer-Acosta Y, Washington AV, Cubano LA, Rodriguez-Orengo J, Dharmawardhane S. The Rac Inhibitor EHop-016 Inhibits Mammary Tumor Growth and Metastasis in a Nude Mouse Model. Transl Oncol. 2014 Oct; 7(5):546-55. PMID: 25389450.
      Citations:    
    17. Martin H, Mali RS, Ma P, Chatterjee A, Ramdas B, Sims E, Munugalavadla V, Ghosh J, Mattingly RR, Visconte V, Tiu RV, Vlaar CP, Dharmawardhane S, Kapur R. Pak and Rac GTPases promote oncogenic KIT-induced neoplasms. J Clin Invest. 2013 Oct; 123(10):4449-63. PMID: 24091327.
      Citations: 28     Fields:    Translation:HumansAnimalsCells
    18. Dharmawardhane S, Hernandez E, Vlaar C. Development of EHop-016: a small molecule inhibitor of Rac. Enzymes. 2013; 33 Pt A:117-46. PMID: 25033803.
      Citations: 19     Fields:    Translation:HumansAnimals
    19. Montalvo-Ortiz BL, Castillo-Pichardo L, Hern?ndez E, Humphries-Bickley T, De la Mota-Peynado A, Cubano LA, Vlaar CP, Dharmawardhane S. Characterization of EHop-016, novel small molecule inhibitor of Rac GTPase. J Biol Chem. 2012 Apr 13; 287(16):13228-38. PMID: 22383527.
      Citations: 123     Fields:    Translation:HumansCells
    20. Hern?ndez E, De La Mota-Peynado A, Dharmawardhane S, Vlaar CP. Novel inhibitors of Rac1 in metastatic breast cancer. P R Health Sci J. 2010 Dec; 29(4):348-56. PMID: 21261173.
      Citations: 21     Fields:    Translation:HumansCells
    21. Vlaar CP, Hern?ndez L. Symposium review: drug discovery, development and clinical research in academia. P R Health Sci J. 2009 Sep; 28(3):268-73. PMID: 19715120.
      Citations: 1     Fields:    
    22. Espinosa S, Solivan M, Vlaar CP. Synthesis and redox-enzyme modulation by amino-1,4-dihydro-benzo[d][1,2]dithiine derivatives. Tetrahedron Lett. 2009 Jun 24; 50(25):3023-3026. PMID: 20161292.
      Citations:    Fields:    
    23. Hern?ndez E, V?lez JM, Vlaar CP. Synthesis of 1,4-dihydro-benzo[d][1,3]oxazin-2-ones from phthalides via an aminolysis-Hofmann rearrangement protocol. Tetrahedron Lett. 2007 Dec 17; 48(51):8972-8975. PMID: 19096499.
      Citations: 3     Fields:    
    Vlaar's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (81)
    Explore
    _
    Co-Authors (10)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

    For technical support please contact support